Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study

被引：0

作者：

Dietrich, Sascha ^{[1
]}

Tilly, Herve ^{[2
,3
]}

Morschhauser, Franck ^{[4
]}

Sehn, Laurie H. ^{[5
,6
]}

Friedberg, Jonathan W. ^{[7
]}

Trneny, Marek ^{[8
]}

Sharman, Jeff ^{[9
]}

Herbaux, Charles ^{[10
]}

Burke, John M. ^{[11
]}

Matasar, Matthew ^{[12
]}

Rai, Shinya ^{[13
]}

Izutsu, Koji ^{[14
]}

Mehta-Shah, Neha ^{[15
]}

Oberic, Lucie ^{[16
]}

Chauchet, Adrien ^{[17
]}

Jurczak, Wojciech ^{[18
]}

Song, Yu Qin ^{[19
]}

Greil, Richard ^{[20
,21
]}

Mykhalska, Larysa ^{[22
]}

Bergua Burgues, Juan Miguel ^{[23
]}

Cheung, Matthew C. ^{[24
]}

Pinto, Antonio ^{[25
]}

Shin, Ho-Jin ^{[26
]}

Hapgood, Greg ^{[27
]}

Munhoz, Eduardo ^{[28
]}

Salles, Gilles ^{[12
]}

机构：

[1] Univ Klinikum Heideberg, Klin Hamatol Onkol Rheumatol, Heidelberg, Germany

[2] Ctr Henri Becquerel, Rouen, France

[3] Univ Rouen, Rouen, France

[4] Univ Lille, Grp Rech Formes Injectables & Technol Associees, CHU Lille, Lille, France

[5] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[6] Univ British Columbia, Vancouver, BC, Canada

[7] UR Med Wilmot Canc Ctr, Rochester, NY USA

[8] Charles Univ Prague, Gen Hosp, Fac Med 1, Prague, Czech Republic

[9] US Oncol, Willamette Valley Canc Inst, Eugene, OR USA

[10] CHU Montpellier, Montpellier, France

[11] US Oncol, Rocky Mt Canc Ctr, Aurora, CO USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

[13] Kindai Univ, Fac Med, Osaka Sayama City, Japan

[14] Natl Canc Ctr, Tokyo, Japan

[15] Washington Univ, St Louis, MO USA

[16] Toulouse Oncopole, Inst Univ Canc, Toulouse, France

[17] CHRU Besancon, Dept Hematol, Besancon, France

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[19] Peking Univ Canc Hosp, Beijing, Peoples R China

[20] Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Salzburg, Austria

[21] Canc Cluster Salzburg, Salzburg, Austria

[22] Clin Hosp Feofaniya, Kiev, Ukraine

[23] Hosp San Pedro Alcantara, Caceres, Spain

[24] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[25] IRCCS, Hematol Oncol Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy

[26] Pusan Natl Univ, Sch Med, Med Res Inst, Pusan Natl Univ Hosp, Busan, South Korea

[27] Princess Alexandra Hosp, Brisbane, Qld, Australia

[28] Hosp Erasto Gaertner, Curitiba, Parana, Brazil

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

891

引用

页码：165 / 165

页数：1

共 50 条

[1] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Flowers, Christopher
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
[2] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta Costa, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher R.
Salles, Gilles
BLOOD, 2021, 138
[3] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
Dietrich, S.
Tilly, H.
Morschhauser, F.
Sehn, L. H.
Friedberg, J.
Trneny, M.
Sharman, J. P.
Herbaux, C.
Burke, J. M.
Matasar, M.
Rai, S.
Izutsu, K.
Mehta-Shah, N.
Oberic, L.
Chauchet, A.
Jurczak, W.
Song, Y.
Greil, R.
Mykhalska, L.
Burgues, J. M. B.
Cheung, M. C.
Pinto, A.
Shin, H-J
Hapgood, G.
Munhoz, E.
Abrisqueta, P.
Gau, J-P
Hirata, J.
Jiang, Y.
Yan, M.
Lee, C.
Flowers, C.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
[4] Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Miguel, Juan
Burgues, Bergua
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher
Salles, Gilles
Collins, Graham
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 14 - 16
[5] Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Friedberg, Jonathan W.
Thompson, Carrie A.
Trneny, Marek
Morschhauser, Franck
Salles, Gilles
Reagan, Patrick M.
Hertzberg, Mark
Smolewski, Piotr
Zhang, Huilai
Thieblemont, Catherine
Hu, Bei
Fonseca, Gustavo
Kim, Won-Seog
Martelli, Maurizio
Mehta, Amitkumar
Campinha-Bacote, Avrita
Yan, Mark
Hirata, Jamie
Sugidono, Matthew
Lee, Calvin
Sharman, Jeff P.
BLOOD, 2022, 140 : 6623 - 6626
[6] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
Tilly, H.
Sharman, J.
Bartlett, N.
Morschhauser, F.
Haioun, C.
Munoz, J.
Chen, A.
Lamy, T.
Wang, L.
Penuel, E.
Hirata, J.
Lee, C.
Salles, G.
HAEMATOLOGICA, 2017, 102 : 4 - 4
[7] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[8] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
Candelaria, Myrna
Duenas-Gonzalez, Alfonso
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[9] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
Tilly, Herve
Morschhauser, Franck
Bartlett, Nancy L.
Sharman, Jeff
Haioun, Corinne
Kolibaba, Kathryn S.
Chen, Andy
Lamy, Thierry
Jones, Surai
Penuel, Elicia
Lee, Calvin
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[10] Epidemiological impact of Polatuzumab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) use in previously untreated Diffuse Large B-cell Lymphoma (DLBCL) on Second Line (2L) treatment: an ad hoc analysis from POLARIX study
Oellerich, T.
Boissard, F.
Tilly, H.
Lenz, G.
Collins, G. P.
Pinto, A.
Sehn, L. H.
Salles, G.
Roussel, M.
Simonella, L.
Ho, R.
Hirata, J.
Lee, C.
Masaquel, A.
Launonen, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 267 - 267

← 1 2 3 4 5 →